Cizzle Bio, Inc.的动态

Cell therapy in the solid tumors has been challenging and numerous next generation options are attempting breakthrough. One exciting novel approach is just about to enter clinical development. MDG1015, a first-in-class, third generation T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1/ LAGE-1a (New York oesophageal squamous cell carcinoma 1 / L Antigen Family Member-1a), armored and enhanced with the PD1-41BB co-stimulatory switch protein (CSP) made by very innovative team at Medigene AG. PhI trail is planned for gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma with IND/CTA filing targeted for 2H 2024. More on MDG1015 is just about to be presented at Immuno-Oncology Summit Europe in few days. #Immunooncology #cell therapy #IND #TCR-T #gastric cancer #ovarian cancer #liposarcoma #sarcoma #oncology clinical development https://lnkd.in/e3sPVD-D

Learn and Grow Blog... Carcinoembryonic Antigen (CEA): Unraveling the Significance in Cancer Detection and Management... In the intricate landscape of cancer diagnosis and treatment, biomarkers play a pivotal role, offering insights into disease progression, response to therapy, and prognosis. One such biomarker that has garnered considerable attention is carcinoembryonic antigen (CEA). Initially discovered over half a century ago, CEA has since emerged as a valuable tool in the battle against cancer, revolutionizing how we detect, monitor, and treat various malignancies. Continue reading it here... https://lnkd.in/gBbeCqm6 #agappe #agappeblogs #learnansgrow

???? CyPath Lung test: A promising tool for early diagnosis of #LungCancer. ???? Early diagnosis of lung cancer is often challenging, as it typically involves a series of comprehensive tests following an initial positive screening result. However, recent advancements in molecular diagnostics, coupled with machine learning techniques, are helping to improve this process. A noteworthy example of these efforts is the CyPath Lung test, which shows promise in streamlining the screening process and facilitating the early detection of lung cancer. CyPath Lung is a non-invasive, sputum-based test that can be used after a positive LDCT test for the early diagnosis of lung cancer. It has 82% sensitivity and 88% specificity for detecting lung cancer in its early stages (I and II) and in cases with nodules less than 20 mm in size. Moreover, it is robust to differences in sample handling which makes it suitable for clinical use. Further more information, read our blog @ https://lnkd.in/dZip2pET and explore the details of the CyPath Lung test and its clinical applications in the early detection of lung cancer. #EarlyDiagnosis #CyPathLung #HealthcareInnovation #CancerScreening #LungHealth #PreventiveCare #NonInvasive #CancerAwareness #LungCancerResearch #HealthTech #LifeSciences #PrecisionMedicine #MedicalAdvancements #HealthcareHeroes #CancerDetection #PublicHealth #Oncology #Biomarkers #HealthInnovation #Bhimar #LifeSciences #Healthcare #LongevityAsia #OmicsFi #CellTalk

Our latest study reveals significant barriers patients encounter in comprehending their diagnosis, primarily due to insufficient information, education, and support. These challenges hinder their ability to self-advocate and participate effectively in shared decision-making. To address these issues, the study recommends several actions: - Enhance Communication: Improve the effectiveness of communication between healthcare professionals (HCPs) and patients. - Empower Patients: Provide patients with the necessary information and guidance to advocate for themselves. - Activate Advocacy Groups: Mobilize local patient advocacy groups to drive change and promote patient advocacy. For more detailed insights, visit the link below.

In this "Eye on Innovation," learn about advancements in endometrial cancer diagnostics, including molecular profiling, the collaborative efforts that led to these innovations, and the groundbreaking impact on patient care. https://bit.ly/49VvdLW

Pulmonary nodules, a risk factor, are increasingly detected,?but hard to distinguish as benign or malignant. ???? Review by Dr. Barbara Guinn et al at Hull York Medical School, University of Hull examines tumor-associated antigens (TAAs) as potential blood #biomarkers for early lung cancer diagnosis. Can advancements in tumor antigen research unlock new possibilities for early-stage lung cancer diagnosis? Share your thoughts! ?? https://lnkd.in/gjtpsdBQ #LungCancer #CancerResearch?#EarlyDetection

Discover how #Veolity can transform lung cancer screening! ?? #Veolity streamlines workflows, reduces reading time, and enhances detection with advanced volumetric quantification of lung nodules and volume doubling time calculations. Meet our MeVis Medical Solutions AG experts at #RANZCR2024, booth #10. We are excited to connect and show you how we are improving lung cancer diagnostics! ?? See you there! #Healthinc #MeVis #Veolity #RadiologyInnovation #RANZCR24 #LungCancerAwareness #LungCancerScreening

Developments in early stage NSCLC are introducing a range of novel options, including new endpoints and algorithms. The integration of biomarkers like PDL1 and drivers, along with concepts like pCR, is aligning lung cancer treatment closer to the advancements seen in breast cancer care. #STOM2024

Sunao Tanaka, PhD from?Cedars-Sinai?presented her research on deploying Oncuria, multiplex immunoassay for the detection and management of bladder cancer, using?Diasorin/Luminex ?'s MAGPIX, Luminex 200 and FLEXMAP 3D units at this year's annual?#AACR2024?meeting in beautiful San Diego. She reported similar readouts regardless of which unit was used to analyze the voided urine sample. This critical research begins to pave the way for additional CLIA labs to onboard our suite of Oncuria tests (Oncuria-Detect to evaluate patients with hematuria; Oncuria-Monitor to surveil patients with a history of bladder cancer; and Oncuria-Predict to determine which patients should receive 1st line BCG therapy). #biotech #multiplex #diagnostics #bladdercancer

Three studies presented at #MAP2024 showcase the potential of circulating tumour cells (CTCs), exosomal microRNA (exo-miRNA), and cell-free RNA (cfRNA) in #CancerDetection and #ProgressionPrediction. ? CTCs in #ColorectalCancer: Significant reductions in CTCs were observed after 3 months of CAPOX treatment in patients with stage III #ColorectalCancer, suggesting CTCs as a valuable prognostic biomarker. ? Exo-miRNA in #BreastCancer: developing an exo-miRNA panel shows promise for metastasis prediction, marking an important step in early cancer detection. ? cfRNA for Multicancer Detection: Innovative cfRNA-based tests are being developed to identify cancer-specific biomarkers, aiming for early and accurate detection. Full commentary by Nicola Fusco on the #ESMODailyReporter ??https://ow.ly/faZw50TMIcq